Ratings Just Issued on these 4 Healthtech Tickers

Tickers Inside If you cannot see this email properly, please click [here]( Dear Reader, Below is a list of 4 Buy Ratings made by some of the Top Analysts on Wall Street for stocks in the HealthTech Sector...Keep in mind, we are not recommending these companies, just reporting what Wall Street Analysts have issued. [For all the latest analyst ratings in the HealthTech Sector, click here](. --------------------------------------------------------------- Sponsorship [What Happened to New Gold Discoveries?]( [See why savvy investors are looking at U.S. gold projects right now.]( --------------------------------------------------------------- [Science 37, SNCE]( Ryan Sigdahl analyst at Craig-Hallum reiterates coverage on [Science 37 (SNCE)](in the Healthcare sector with a Buy rating. TipRanks.com has Sigdahl rated as a 4.8 star analyst with a 53% return on investment and a 21.1% success rate. Sigdahl has not provided a price target. [TipRanks.com]( reports that [Science 37](currently has 3 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $25.00. In addition, TradingView issued a buy rating for [SNCE]( over the next month, Barchart.com has a Weak sell rating and Yahoo! Finance has a Bearish short-term outlook. [Get the full story on other analysts covering SNCE by clicking here.]( --------------------------------------------------------------- [Savara, SVRA]( Liisa Bayko analyst at Evercore ISI reiterates coverage on [Savara (SVRA)](in the Healthcare sector with a Buy rating. TipRanks.com has Bayko rated as a 4.4 star analyst with a 45% return on investment and a 8.3% success rate. Bayko has set a price target of $7. [TipRanks.com]( reports that [Savara](currently has 5 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $6.70. In addition, TradingView issued a buy rating for [SVRA]( over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bullish short-term outlook. [Get the full story on other analysts covering SVRA by clicking here.]( --------------------------------------------------------------- Sponsorship [The Gold Dilemma Nobody Told You About]( flock to gold during times of uncertainty, instability, and geopolitical crisis. We saw this with the COVID-19 pandemic, the Russia-Ukraine war, and now the Israel-Hamas conflict. While analysts are increasingly bullish on the yellow metal, new gold discoveries are urgently needed to meet the projected future demand. [Read about this potential new American gold hotspot.]( --------------------------------------------------------------- [Ultragenyx Pharmaceutical, RARE]( Ed Arce analyst at H.C. Wainwright reiterates coverage on [Ultragenyx Pharmaceutical (RARE)](in the Healthcare sector with a Buy rating. [TipRanks.com]( has Arce rated as a 4.4 star analyst with a 42% return on investment and a 7.6% success rate. Arce has set a price target of $82. [TipRanks.com]( reports that [Ultragenyx Pharmaceutical](currently has 5 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $95.80. In addition, TradingView issued a buy rating for [RARE]( over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bearish short-term outlook. [Get the full story on other analysts covering RARE by clicking here.]( --------------------------------------------------------------- [Boston Scientific, BSX]( Josh Jennings analyst at TD Cowen reiterates coverage on [Boston Scientific (BSX)](in the Healthcare sector with a Buy rating. [TipRanks.com]( has Jennings rated as a 4.1 star analyst with a 54% return on investment and a 4.4% success rate. Jennings has set a price target of $65. [TipRanks.com]( reports that [Boston Scientific](currently has 5 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $68.60. In addition, TradingView issued a buy rating for [BSX]( over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bearish short-term outlook. [Get the full story on other analysts covering BSX by clicking here.]( --------------------------------------------------------------- Sponsorship [GPT-4 vs. X.AI: The Race of the New AI Giants]( smart money investors all know AI is the wave of the future and could mean huge profits for anyone involved. AI has been called the biggest new industry of the 21st century. Experts are projecting it will be worth a staggering $80 trillion over the next 10 years. And right now, Chief Investment Strategist Adam O’Dell is revealing his favorite X.AI stock you should check out today. [Click here to see the full story now.]( --------------------------------------------------------------- Just a reminder, one resource you need to consider using [Tipranks.com]( where as a premium member you get access to all buy ratings, price targets and insider trading signals. [Click here for more on Tipranks.com.]( Another great tool for charting is [TradingView.com](, and for more news [Google Finance](, so you might want to check that out too. To you financial future! The Editor --------------------------------------------------------------- Sponsorship [More "Safe" Gold is Needed to Meet Growing Demand]( is an effective way to protect portfolios from the forces of war and uncertainty. But gold reserves have declined, along with a lack of new gold discoveries. To make up for growing gold demand, more new mining projects and gold discoveries are needed - particularly in safe jurisdictions such as the U.S. [See why American gold should be on every investor's radar.]( --------------------------------------------------------------- HealthTechMovers.com Disclaimer This newsletter contains advertisements which are neither an offer nor recommendation to buy or sell any security. Content marked as "Ad," "Special" or "Sponsor" may be a third party advertisements where the advertiser is paying per click, per lead or per sale and are not endorsed or warranted by our staff or company. Sandpiper Marketing Group, LLC is also being compensated by Summit Publishing Group and Investing Trends up to three dollars per click and may exceed twelve thousand, five hundred dollars per week for placement of specific advertisements contained in this newsletter. Sandpiper Marketing Group, LLC and its principles do not own any of the stocks mentioned in this email or in the article that this email links to. Please see the disclaimer on the advertiser's website for additional information, including their relationship with any mentioned security. Compensation for advertising constitutes a conflict of interest as to our ability to remain objective in our communication regarding any companies profiled. Because of this conflict, individuals are strongly encouraged to not use this newsletter as the basis for any investment decision. This newsletter may contain information regarding investment ideas and third-party ratings regarding specific securities. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. Sandpiper Marketing Group, LLC nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from Sandpiper Marketing Group, LLC to buy or sell any security. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. The content in this newsletter or email is not provided to any individual with a view toward their individual circumstances. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. [If you are not a human, click here.]( By opening this email or clicking any links contained, you are reconfirming your opt-in status. You can unsubscribe at any time by clicking the link below in the footer. Sandpiper Marketing Group, LLC | 1519 Mecklenburg Hwy | Unit 4 | Mt. Mourne | NC | 28123 | United States | 8774119808 [Unsubscribe]( | [Report spam]( Sent with [ActiveTrail]( software